A 3-month, multicenter, randomized, open-label study to evaluate the impact on wound healing of the early (vs delayed) introduction of everolimus in De Novo Kidney transplant recipients, with a follow-up evaluation at 12 months after transplant (NEVERWOUND study)

Tommaso Maria Manzia, Mario Carmellini, Paola Todeschini, Antonio Secchi, Silvio Sandrini, Enrico Minetti, Lucrezia Furian, Gionata Spagnoletti, Francesco Pisani, Gian Benedetto Piredda, Gianni Cappelli, GIuseppe Tisone

Research output: Contribution to journalArticlepeer-review

Abstract

Background. The risk of wound healing complications (WHCs) and the early use of mammalian target of rapamycin inhibitors after kidney transplantation (KT) have not been fully addressed. Methods. The NEVERWOUND study is a 3-month, multicenter, randomized, open-label study designed to evaluate whether a delayed (ie, 28 ± 4 d posttransplant) immunosuppression regimen based on everolimus (EVR) reduces the risk of WHC versus EVR started immediately after KT. Secondary endpoints were treatment failure (biopsy-proven acute rejection, graft loss, or death), delayed graft function, patient and graft survival rates, and renal function. Results. Overall, 394 KT recipients were randomized to receive immediate (N = 197) or delayed (N = 197) EVR after KT. At 3 months, WHC-free rates in the immediate EVR versus delayed EVR arm, considering the worst- and best-case scenario approach, were 0.68 (95% confidence interval [CI], 0.62-0.75) versus 0.62 (95% CI, 0.55-0.68) (log-rank P = 0.56) and 0.70 (95% CI, 0.64-0.77) versus 0.72 (95% CI, 0.65-0.78) (log-rank P = 0.77), respectively. The 3- and 12-month treatment failure rates, delayed graft function and renal function, and patient and graft survival were not different between the arms. Conclusions. The early introduction of EVR after KT did not increase the risk of WHC, showing good efficacy and safety profile.

Original languageEnglish
Pages (from-to)374-386
Number of pages13
JournalTransplantation
DOIs
Publication statusAccepted/In press - 2020

ASJC Scopus subject areas

  • Transplantation

Fingerprint Dive into the research topics of 'A 3-month, multicenter, randomized, open-label study to evaluate the impact on wound healing of the early (vs delayed) introduction of everolimus in De Novo Kidney transplant recipients, with a follow-up evaluation at 12 months after transplant (NEVERWOUND study)'. Together they form a unique fingerprint.

Cite this